Bausch+Lomb Results Presentation Deck
1Q23 Revenue Drivers
Total Company Revenue
Millions USD
5%
8%
889
1Q22²
931
1Q23
1Q23 Reported
Revenue Growth
1Q23 Constant Currency
Revenue Growth ¹
High-quality growth across all three
segments and most of our significant
markets around the world
BAUSCH + LOMB
• China recovery in progress with a gradual
recovery seen throughout 1Q23
$31M headwind from FX to revenue
Vision Care
+8%
Constant currency
revenue growth ¹
Surgical
+9%
Constant currency
revenue growth ¹
Ophthalmic
Pharma
+7%
Constant currency
revenue growth ¹
Lumify® (+23% reported revenue growth)
Daily SiHy (+38% reported revenue growth)
Bausch + Lomb ULTRA® (+16% reported revenue growth; +18% constant currency¹)
• Biotrue® ONEday (+6% reported revenue growth; +8% constant currency¹)
Artelac® (+25% reported revenue growth; +29% constant currency¹)
• Market leadership in key categories, including PreserVision®, Lumify® and Biotrue®
multi-purpose solution with #1 market share in U.S.³
• Growth in implantables (-2% reported revenue decline; +2% constant currency¹),
driven by premium I0Ls
• Strong demand for consumables (+9% reported revenue growth;
+13% constant currency¹), including Stellaris® and custom packs as well as
improving supply
Equipment (+5% reported revenue growth; +7% constant currency¹)
Early stages of IC-8® Apthera ™M IOL launch generating strong interest
●
●
Vyzulta® saw +25% reported revenue growth; geo-expansion
• Capitalized on competitor supply challenges in the U.S. generic market
• Growth in International portfolio primarily driven by Minims franchise which saw 7%
reported revenue growth; +14% constant currency¹
1. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information non-GAAP measures and ratios.
2. 1022 results were not fully burdened by all of the stand-up costs associated with the separation..
3. National Consumer Panel from IRI.
8View entire presentation